Sign up Australia
Proactive Investors - Run By Investors For Investors

Medlab Clinical initiates study of cholesterol lowering oral spray

Worldwide statin market estimated at US$12 billion in 2018.
Medlab Clinical initiates study of cholesterol lowering oral spray
Oral spray expected to remove side effects of statins

Medlab Clinical (ASX:MDC) has signed an agreement to initiate a study to compare how its atorvastatin oral spray compares with statin tablets, like Lipitor, the off-patent market leader.

Statins are a class of drugs often prescribed by doctors to help lower cholesterol levels in the blood. By lowering the levels, they help prevent heart attacks and stroke.

The size of the statin market worldwide, predominantly comprised of tablets, is significant and has been estimated at US$12 billion in 2018.

Medlab’s research to date indicates that a more direct oral spray will enable smaller doses and by reducing dosage, remove much of the statin side effects, reported by about one-third of patients.

The testing of Medlab’s atorvastatin oral spray has been promising, but an independent study is expected to provide objective evidence for those pharma companies which have shown interest.

Medlab’s study agreement is with Zenith Technology Corporation of Dunedin New Zealand, a certified research organisation which does clinical trials and analysis.

Incidentally, Medlab is also completing the final steps to start Australia’s first clinical trial using cannabis for oncology patients suffering intractable pain.

The company’s efforts have been supported by the federal government’s recent announcement to facilitate faster supply of medicinal cannabis products.

Medlab recently obtained clearances from Australian health departments and is awaiting a final shipment clearance from Canadian health authorities to import cannabis material from Canada.

The company’s share price has more than doubled during the past six months, last trading at $0.84.



Register here to be notified of future MDC Company articles
View full MDC profile View Profile

Medlab Clinical Timeline

Related Articles

stem cell
June 12 2017
"With multiple value upside triggers ahead, including imminent maiden revenues from CellPlan, I very much look forward to the opportunities ahead" - CEO João Andrade
Cells
May 17 2017
Revenues are on the rise and the group’s efforts to bring in new business is delivering.
Genetic data
July 12 2016
Drug discovery company snaps up software system for "non-material" sum

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use